William Arnold

Dr. William Arnold

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2024 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
WAWilliam Arnold
William Arnold
AMAdamo Mancino
Adamo Mancino
FMFrank R. Moss
Frank R. Moss
AFAdam Frost
Adam Frost
DJDavid Julius
David Julius
YCYifan Cheng
Yifan Cheng
TRP ion channels are modulated by phosphoinositide lipids, but the underlying structural mechanisms remain unclear. The capsaicin- and heat-activated receptor, TRPV1, has served as a model for deciphering lipid modulation, which is relevant to understanding how pro-algesic agents enhance channel activity in the setting of inflammatory pain. Identification of a pocket within the TRPV1 transmembrane core has provided initial clues as to how phosphoinositide lipids bind to and regulate the channel. Here we show that this regulatory pocket in rat TRPV1 can accommodate diverse lipid species, including the inflammatory lipid lysophosphatidic acid, whose actions are determined by their specific modes of binding. Furthermore, we show that an empty-pocket channel lacking an endogenous phosphoinositide lipid assumes an agonist-like state, even at low temperature, substantiating the concept that phosphoinositide lipids serve as negative TRPV1 modulators whose ejection from the binding pocket is a critical step toward activation by thermal or chemical stimuli.

4 October 2018 in Biochemistry
Verified
Journal Article
Closed access
Lauren N CarnevaleLauren N Carnevale
Lauren N Carnevale
AAAndres S. Arango
Andres S. Arango
WAWilliam Arnold
William Arnold
Emad TajkhorshidEmad Tajkhorshid
Emad Tajkhorshid
ADAditi Das
Aditi Das

9 April 2018 in Biochemistry
Verified
Journal Article
Closed access
WAWilliam Arnold
William Arnold
ADAditi Das
Aditi Das

1 January 2016 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
LPLisa Plucinski
Lisa Plucinski
Manas GartiaManas Gartia
Manas Gartia
WAWilliam Arnold
William Arnold
AAAbid Ameen
Abid Ameen
TCTe-Wei Chang
Te-Wei Chang
ADAditi Das
Aditi Das

Verified
Journal Article
Open access
PDF file
WAWilliam Arnold
William Arnold
SZSusan Zelasko
Susan Zelasko
DMDaryl D. Meling
Daryl D. Meling
KSKimberly Sam
Kimberly Sam
ADAditi Das
Aditi Das
Cytochrome P450 2C8 (CYP2C8) epoxygenase is responsible for the metabolism of over 60 clinically relevant drugs, notably the anticancer drug Taxol (paclitaxel, PAC). Specifically, there are naturally occurring polymorphisms, CYP2C8*2 and CYP2C8*3, that display altered PAC hydroxylation rates despite these mutations not being located in the active site. Herein, we demonstrate that these polymorphisms result in a greater uncoupling of PAC metabolism by increasing the amount of hydrogen peroxide formed per PAC turnover. Anaerobic stopped-flow measurements determined that these polymorphisms have altered first electron transfer kinetics, compared to CYP2C8*1 (wildtype), that suggest electron transfer from cytochrome P450 reductase (CPR) is disfavored. Therefore, these data demonstrate that these polymorphisms affect the catalytic cycle of CYP2C8 and suggest that redox interactions with CPR are disrupted.

7 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
WAWilliam Arnold
William Arnold
LCLauren N. Carnevale
Lauren N. Carnevale
ZXZili Xie
Zili Xie
JBJavier L. Baylon
Javier L. Baylon
Emad TajkhorshidEmad Tajkhorshid
Emad Tajkhorshid
ADAditi Das
Aditi Das
The endocannabinoid (eCB) system is a promising target to mitigate pain as the eCBs are endogenous ligands of the pain-mediating receptors—cannabinoid receptors 1 and 2 (CB1 and CB2) and TRPV1. Here we report on a novel class of lipids formed by the epoxidation of N-arachidonoyl-dopamine (NADA) and N-arachidonoyl serotonin (NA5HT) by cytochrome P450 (CYP) epoxygenases. These epoxides (epoNADA and epoNA5HT) are dual-functional rheostat modulators (varying strength of agonism or antagonism) of the eCB-TRPV1 axis. In fact, epoNADA is a 6-fold stronger agonist of TRPV1 than NADA while epoNA5HT is a 30-fold stronger antagonist of TRPV1 than NA5HT and displays a significantly stronger inhibition on TRPV1-mediated responses in primary afferent neurons. Moreover, epoNA5HT is a full CB1 agonist. The epoxides reduce the pro-inflammatory biomarkers IL-6, IL-1β, TNF-α and nitrous oxide (NO) and raise anti-inflammatory IL-10 in activated microglial cells. The epoxides are spontaneously generated by activated microglia cells and their formation is potentiated in the presence of another eCB, anandamide (AEA). We provide evidence for the direct biochemical mechanism of this potentiation using human CYP2J2, a CYP epoxygenase in the human brain, using detailed kinetics studies and molecular dynamics simulations. Taken all together, inflammation leads to an increase in the metabolism of NADA, NA5HT and other eCBs by CYP epoxygenases to form the corresponding epoxides. The epoxide metabolites are bioactive lipids that are more potent, multi-faceted endogenous molecules, capable of influencing the activity of CB1, CB2 and TRPV1 receptors. The identification of these molecules will serve as templates for the synthesis of new multi-target therapeutics for the treatment of inflammatory pain.